Fenofibrate-induced liver injury

查看全文 作　　者：Kazufumi [1]Dohmen;Chun Yang [2]Wen;Shinya [2]Nagaoka;Koji [2]Yano;Seigo [2]Abiru;Toshihito [2]Ueki;Atsumasa [2]Komori;Manabu [2]Daikoku;Hiroshi [2]Yatsuhashi;Hiromi [2]Ishibashi

机构地区：[1]Internal Medicine, Okabe Hospital, 1-2-1 Myojinzaka Umi-machi Kasuya-gun Fukuoka 811-2122, Japan;[2]Clinical Research center, National Nagasaki Medical Center, Omura 856-8562, Japan

出　　处：《World Journal of Gastroenterology》索引2005年第11卷第48期,共2页

摘　　要：TO THE EDITOR Fenofibrate is a member of such fibrate class agents as bezafibrate and it work as a ligand of PPARα, and also shows a potent triglyceride-lowering effect. The elevation of aminotransferase levels has been frequently observed after the administration of fenofibrate and this phenomenon is considered to be non-pathological because fenofibrate activates the gene expression of the aminotransferases. Recently, fenofibrate has been used not only for hypercholesterolemia but also for primary biliary cirrhosis (PBC)[1,2]. However, the occurrence of liver injury induced by fenofibrate has not yet been reported written in the English literature. We herein report a rare case of liver injury due to the oral use of this drug. 关键词：肝炎损伤病理机制治疗临床表现

相关文献

参考文献（9）
引证文献（7）
耦合文献（11）

参考文献(9)

引证文献(7)

耦合文献(11)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Fenofibrate-induced liver injury

参考文献(9)

引证文献(7)

耦合文献(11)

用户提示